TRVN

Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical

Hit By The Pandemic, Trevena Restarts Opioid Use Disorder Program After More Than A Year

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021

Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2021 Results - Earnings Call Transcript

TRVN Stock: 2.82% Increase (From $1.77 To $1.82) Pre-Market Explanation